Skip to main content

Table 4 Fold-change of proteins in forbesione- and/or doxorubicin-treated vs. DMSO-treated KKU-100 cells

From: Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines

   KKU-100 cell
Proteins Treatments Fold-changes of proteins in treated vs. control cells
   Concentration of forbesione or doxorubicin (μM)
  Forbesione 0.25 0.50 1.00
Doxorubicin 0.006 0.012 0.025
Forb + Dox C1 C2 C3
Bcl-2 Forbesione 0.63a 0.60a 0.27c
  Doxorubicin 0.76 0.68b 0.25c
  Forb + Dox 0.74a 0.65b,–,* 0.10c,*,*
Bax Forbesione 1.56a 2.06b 2.06c
  Doxorubicin 1.87a 2.07a 2.17a
  Forb + Dox 2.35c 2.37c,*,* 3.24c,*,*
Bax/Bcl-2 Forbesione 0.53b 0.73a 1.63c
  Doxorubicin 0.84a 1.03 2.87c
  Forb + Dox 1.18 1.35a,*,– 12.00c,*,*
survivin Forbesione 0.96 0.78a 0.35c
  Doxorubicin 1.00 0.97 0.24c
  Forb + Dox 0.97 0.41a,*,* 0.13c,*,*
Procaspase-9 Forbesione 0.92 0.79a 0.70a
  Doxorubicin 0.90 0.71a 0.65a
  Forb + Dox 0.69 0.68 0c,*,*
Activated Forbesione 10.00c 39.00c 42.00c
caspase-9  Doxorubicin 22.00c 48.00c 51.00c
  Forb + Dox 50.00c 50.00c,*,– 64.00c,*,*
Procaspase-3 Forbesione 1.00 0.99 0.76a
  Doxorubicin 0.98 0.76 0.69a
  Forb + Dox 0.97 0.74a,*,– 0c,*,*
Activated Forbesione 9.00c 9.00c 42.00c
caspase-3 Doxorubicin 20.00c 40.00c 50.00c
  Forb + Dox 15.00c 47.00c,*,– 54.00c,*,*
IκB-α Forbesione 1.05 1.07 1.15
  Doxorubicin 1.03 1.06 1.12
  Forb + Dox 1.16a 1.21b,–,* 1.21b,*,*
pIκB-α Forbesione 0.97 0.97 0.14b
  Doxorubicin 0.58a 0.58a 0.14b
  Forb + Dox 0.25c 0.01c,*,* 0.01c,*,*
NF-κB/p65 Forbesione 1.00 0.78b 0.12b
  Doxorubicin 1.00 1.00 1.00
  Forb + Dox 0.95 0.01c,*,* 0.01c,*,*
MRP1 Forbesione 0.89a 0.79a 0.71a
  Doxorubicin 1.00 0.96 0.82a
  Forb + Dox 0.75a 0.74b,–,* 0.34c,*,*
  1. Data = The mean ratio of the density readings of target proteins normalized to β-actin from the forbesione- and/or doxorubicin-treated to DMSO-treated cells (n = 3). aP < 0.05, bP < 0.01, cP < 0.001 vs. DMSO-treated cells. Comparison between forbesione or doxorubicin treatment alone and combined drug treatment indicated by *,*P < 0.05 respectively, not significant difference indicated by “”.